Citation: Egorova, Svetlana, Timinouni, Mohammed, Demartin, Marie, Granier, Sophie, Whichard, Jean, Sangal, Vartul, Fabre, Laëtitia, Delauné, Aurélia, Pardos, Maria, Millemann, Yves, Espié, Emmanuelle, Achtman, Mark, Grimont, Patrick and Weill, François-Xavier (2008) Ceftriaxone-resistant salmonella enterica serotype Newport, France. Emerging Infectious Diseases, 14 (6). pp. 954-7. ISSN 1080-6059

Published by: Centres for Disease Control and Prevention

URL: http://dx.doi.org/10.3201/eid1406.071168 <http://dx.doi.org/10.3201/eid1406.071168>

This version was downloaded from Northumbria Research Link: http://nrl.northumbria.ac.uk/14513/

Northumbria University has developed Northumbria Research Link (NRL) to enable users to access the University's research output. Copyright © and moral rights for items on NRL are retained by the individual author(s) and/or other copyright owners. Single copies of full items can be reproduced, displayed or performed, and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided the authors, title and full bibliographic details are given, as well as a hyperlink and/or URL to the original metadata page. The content must not be changed in any way. Full items must not be sold commercially in any format or medium without formal permission of the copyright holder. The full policy is available online: http://nrl.northumbria.ac.uk/policies.html

This document may differ from the final, published version of the research and has been made available online in accordance with publisher policies. To read and/or cite from the published version of the research, please visit the publisher’s website (a subscription may be required.)
Ceftriaxone-Resistant Salmonella enterica Serotype Newport, France

Svetlana Egorova,*1 Mohammed Timinouni,*2 Marie Demartin,* Sophie A. Granier,† Jean M. Whichard,‡ Vartul Sangal,§ Laëtitia Fabre,* Aurélia Delauné,* Maria Pardos,* Yves Millemann,¶ Emmanuelle Espié,# Mark Achtman,§** Patrick A.D. Grimont,* and François-Xavier Weill*

The multidrug-resistant (MDR) Salmonella enterica serotype Newport strain that produces CMY-2 β-lactamase (Newport MDR-AmpC) was the source of sporadic cases and outbreaks in humans in France during 2000–2005. Because this strain was not detected in food animals, it was most likely introduced into France through imported food products.

Third-generation cephalosporins are drugs of choice for treatment of persons with nontyphoidal Salmonella infections that require chemotherapy or when fluoroquinolones are contraindicated. A new public health concern is the emergence of third-generation cephalosporin–resistant Salmonella isolates (1). Multidrug-resistant (MDR) Salmonella enterica serotype Newport isolates that produce CMY-2, a β-lactamase that inactivates third-generation cephalosporins, were first reported in the United States in 1998 (2). These isolates, known as Newport MDR-AmpC, have quickly spread through the United States in cattle and humans (3–5). It has been hypothesized that use of ceftriaxone, a third-generation cephalosporin licensed in the United States for use in cattle, could have selected for Newport MDR-AmpC (2–4,7). Several observations and case-control studies suggested beef and milk from dairy cattle were substantial sources of Newport MDR-AmpC infection in humans (6–8).

These isolates seem to be extremely rare in Europe. Two surveys performed in England and Wales (278,308 human Salmonella isolates tested, 1992–2003) and Spain (959 human Salmonella isolates, 1999–2000) did not detect Newport MDR-AmpC (9,10). In St. Petersburg, Russia, only 1 Newport MDR-AmpC isolate was reported among 1,078 Salmonella isolates during 2002–2005 (11). In France, a small outbreak (14 cases) of Newport MDR-AmpC was detected in 2003 and linked to consumption of imported horse meat (12). We undertook the present study to acquire more knowledge on circulation of Newport MDR-AmpC in humans, animals, and animal-derived food in France.

The Study

From 2000 through 2005, the French National Reference Centre for Salmonella at the Institut Pasteur in Paris reported 829 Newport isolates among 69,759 Salmonella clinical isolates. During this period and depending on the year, serotype Newport ranked between 6th and 10th in prevalence among human serotyped isolates. From 2000 through 2005, the Agence Française de Sécurité Sanitaire des Aliments reported 2,160 Newport isolates among 101,791 Salmonella isolates collected from animals and food products.

Antimicrobial drug susceptibility testing was performed on 585 human Newport isolates and 342 nonhuman Newport isolates by disk diffusion with 32 antimicrobial drugs (additional information available from fxweill@pasteur.fr). Data for Newport human isolates are shown in the Table. Of 585 isolates tested, 46 (7.9%) were resistant to third-generation cephalosporins. The geographic origin of the isolates was mainly the Paris metropolitan area and northern France (online Appendix Table, available from www.cdc.gov/EID/content/14/6/954-appT.htm). There was a high prevalence of third-generation cephalosporin–resistant isolates during 2000 (15%) and 2003 (17.5% caused by a small outbreak). No third-generation cephalosporin resistance was detected in any of the nonhuman Newport isolates tested.

Experiments were performed on the 46 third-generation cephalosporin–resistant Newport isolates (additional information available from fxweill@pasteur.fr). All but 1 of the Newport isolates were resistant to cefoxitin (online Appendix Table). These isolates showed 4 resistance phenotypes; most (41, 89.1%) were resistant to streptomycin, sulfonamides, chloramphenicol, and tetracycline. PCR and sequencing showed that the 45 isolates resistant to cefoxitin were positive for the bla _CMY-2_ gene, and cefoxitin-susceptible isolates contained the extended-spectrum β-lactamase gene _bla _CTX-M-1_. Ceftriaxone MICs of Newport MDR-AmpC isolates ranged from 32 mg/L to >256 mg/L, and ceftazidime MICs ranged from 64 mg/L to >256 mg/L. No _bla _TEM genes were detected. Three isolates with additional resistance to aminoglycosides contained a class 1 integron with the 1-kb gene cassette _aadA24_ (known to encode resistance to strep-
Clonal relatedness of Newport isolates was assessed by multilocus sequence typing (MLST) and PulseNet standard method pulsed-field gel electrophoresis (PFGE) (Figure 1). All 16 Newport MDR-AmpC isolates tested had a common sequence type (ST), ST45. XbaI-PFGE identified 10 distinct profiles (similarity 76.7%) among all 45 Newport MDR-AmpC isolates. Single enzyme matches were found for 3 of the profiles (15 isolates) in the US PulseNet national database (www.cdc.gov/pulsenet; online Appendix Table; Figure 2). Two PFGE types (New6 and New8) were divided into 2–4 subtypes because of additional band(s) <100 kb. Isolates from the 2003 outbreak showed 4 similar but distinct PFGE profiles that differed by 1–2 bands, migrated between 60 and 100 kb, and were attributed to plasmid(s) (additional information available from fxweill@pasteur.fr). If only cases with indistinguishable PFGE profiles had been tested, potentially related cases would not have been linked to this outbreak. Therefore, during an outbreak investigation of Newport MDR-AmpC, analysis of plasmid content (either by alkaline lysis or S1 nuclease, depending on size of additional bands) might complete XbaI-PFGE profiles for isolates whose profiles differ by 1 or 2 additional bands of low molecular mass.

Alkaline lysis extraction showed that all but 1 of the Newport MDR-AmpC isolates harbored a plasmid >125 kb that hybridized with a blaCMY-2 probe; the remaining isolate harbored a plasmid of 100 kb (online Appendix Table). Analysis with S1 nuclease showed that these plasmids were >100 kb–370 kb. Up to 3 additional plasmids (3.5 kb–100 kb) that did not have blaCMY-2 were detected in most isolates (online Appendix Table). Cephalosporin resistance was transferred by electroporation of plasmid DNA to Escherichia coli DH10B for all 38 CMY-2–positive isolates tested. When present in the donor strain, resistance to sulfonamides, chloramphenicol, and tetracycline was also transferred. Restriction analysis of plasmids isolated from transformants showed 6 similar restriction profiles for Newport isolates (R1–R6) (Figure 2, online Appendix Table). R1 was predominant (found in 26 isolates among 35 tested, 74.3%). Newport plasmids R1–R6 and Agona plasmid R8 were shown by PCR to contain variant A/C2 replicons (13), whereas Typhimurium plasmid R7 contained the I1 replicon.

Pros1-digested plasmids analyzed by Southern hybridization with a blaCMY-2 probe (Figure 2) showed 4 hybridization profiles among Newport isolates. Profile H1 corresponded to plasmid type C described by Carattoli et al. (14). Profiles H2, H3, and H4 differed from H1 by 1 additional band (>10 kb for H2, 3.2 kb for H3, and >18 kb for H4), which indicated that the blaCMY-2 gene was partially or totally duplicated.

Conclusions

Newport MDR-AmpC isolates have been the source of sporadic cases and small outbreaks in humans in France during 2000–2005. All isolates had the same MLST type, ST45, and highly similar XbaI-PFGE profiles. Their plasmids were >100 kb–370 kb. Up to 3 additional plasmids (3.5 kb–100 kb) that did not have blaCMY-2 were detected in most isolates (online Appendix Table). Cephalosporin resistance was transferred by electroporation of plasmid DNA to Escherichia coli DH10B for all 38 CMY-2–positive isolates tested. When present in the donor strain, resistance to sulfonamides, chloramphenicol, and tetracycline was also transferred. Restriction analysis of plasmids isolated from transformants showed 6 similar restriction profiles.

<table>
<thead>
<tr>
<th>Drug</th>
<th>2000 (n = 100)</th>
<th>2001 (n = 124)</th>
<th>2002 (n = 66)</th>
<th>2003 (n = 126)</th>
<th>2004 (n = 91)</th>
<th>2005 (n = 78)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(N = 109)</td>
<td>(N = 134)</td>
<td>(N = 71)</td>
<td>(N = 138)</td>
<td>(N = 94)</td>
<td>(N = 80)</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>27</td>
<td>9.7</td>
<td>1.5</td>
<td>19.8</td>
<td>8.8</td>
<td>3.8</td>
</tr>
<tr>
<td>Ceftriaxone/cefaziomide</td>
<td>15</td>
<td>4</td>
<td>1.5</td>
<td>17.5</td>
<td>2.2</td>
<td>0</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>4</td>
<td>1.6</td>
<td>0</td>
<td>1.6</td>
<td>2.2</td>
<td>0</td>
</tr>
<tr>
<td>Nalidixic acid</td>
<td>23</td>
<td>7.3</td>
<td>4.5</td>
<td>1.6</td>
<td>4.4</td>
<td>2.6</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Sulfonamides</td>
<td>29</td>
<td>10.5</td>
<td>4.5</td>
<td>19.8</td>
<td>8.8</td>
<td>0</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>10</td>
<td>4</td>
<td>3</td>
<td>1.6</td>
<td>4.4</td>
<td>0</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>25</td>
<td>9.7</td>
<td>1.5</td>
<td>15.9</td>
<td>8.8</td>
<td>0</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>27</td>
<td>11.3</td>
<td>3</td>
<td>19</td>
<td>9.9</td>
<td>3.8</td>
</tr>
</tbody>
</table>

*In, no. of isolates studied; N, no. of isolates received at the French National Reference Centre for Salmonella (1 per patient).
mids carrying $bla_{CMY-2}$ were homogeneous (same incompatibility group A/C2, a main restriction type R1, and a main hybridization type H1). These results support clonal expansion of 1 Newport strain (or a limited number of genetically related Newport strains) able to acquire and maintain a large incA/C2 MDR plasmid.

The source of the French isolates remains unknown. However, this strain was not found in French food animals or domestically produced food products (additional information available from fxwell@pasteur.fr). One outbreak during the study period was linked to imported horse meat. Further investigation identified the source as a wholesaler who imported meat from Belgium, the United Kingdom, Hungary, Canada, Brazil, Argentina, Uruguay, and Australia (12). In contrast to Europe, Newport MDR-AmpC has been frequently seen in the United States during the past decade. Furthermore, several characteristics were shared between US and French Newport MDR-AmpC isolates: ST45 (15), PFGE profiles New5, New6a, and New6b (displayed by 15 isolates among the 45 studied), and $bla_{CMY-2}$ plasmid hybridization type H1 (14). We can reasonably hypothesize that during 2000–2005 some isolates likely entered France from North America through imported food. Alternatively, they could have come to France and North America from some other country.

Acknowledgments

We thank all corresponding laboratories of the French National Reference Centre for Salmonella and the Agence Française de Sécurité Sanitaire des Aliments networks for participation in the study, and Peter Gerner-Smidt for comparing PFGE profiles with those of the PulseNet USA database.

S.E. and M.T. were supported by a grant from the Réseau International des Instituts Pasteur. M.A. was supported by grant 05/FI/155 from the Science Foundation of Ireland.

Dr Egorova is a microbiologist in the laboratory of intestinal infections at the Institut Pasteur in St. Petersburg, Russia. Her primary research interests are molecular epidemiology and antimicrobial resistance surveillance of S. enterica.

References


Address for correspondence: François-Xavier Weill, Centre National de Référence des Salmonella, Laboratoire des Bactéries Pathogènes Entériques, Institut Pasteur, 28 Rue du Docteur Roux, 75724 Paris CEDEX 15, France; email: fxweill@pasteur.fr

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.